Early Intervention with High-Dose Steroid Pulse Therapy Prolongs Disease-Free Interval of Severe Alopecia Areata: A Retrospective Study

被引:18
|
作者
Yang, Chao-Chun [1 ,2 ]
Lee, Chun-Te [1 ]
Hsu, Chao-Kai [1 ,2 ]
Lee, Yi-Pei [1 ]
Wong, Tak-Wah [1 ]
Chao, Sheau-Chiou [1 ]
Lee, Julia Yu-Yun [1 ]
Sheu, Hamm-Ming [1 ]
Chen, WenChieh [3 ]
机构
[1] Natl Cheng Kung Univ, Coll Med, Dept Dermatol, Tainan 70101, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan 70101, Taiwan
[3] Tech Univ Munich, Dept Dermatol & Allergy, D-80802 Munich, Germany
关键词
Alopecia areata; Corticosteroids; Pulse drug therapy; Treatment; CORTICOSTEROID-THERAPY; GUIDELINES; MANAGEMENT;
D O I
10.5021/ad.2013.25.4.471
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Spontaneous recovery of severe alopecia areata is rare and the condition is difficult to treat. Objective: The aim of this study is to investigate and compare the effects and safety of steroid pulse therapy between oral and intravenous administrations between 1999 and 2010 at the Department of Dermatology, National Cheng Kung University Hospital. Methods: Data were retrospectively retrieved. A satisfactory response was defined as more than 75% hair regrowth in the balding area. Results: A total of 85 patients with more than 50% hair loss were identified and treated, with an overall satisfactory response rate of 51.8%. The mean follow-up time was 37.6 months, with a relapse rate of 22.7%. Patients with alopecia areata (hereafter, AA) of recent onset within one year showed higher response rates (p<0.001) and lower relapse rates compared to patients with AA persisting for more than 1 year. Further, even in patients with alopecia totalis, alopecia universal is or ophiasis type, early treatment resulted in a satisfactory response rate of 47% among the treated patients. In general, oral therapy was as effective and well-tolerated as intravenous therapy. Conclusion: The response rate is determined by disease severity and time of intervention, not by the administration form of steroid pulse therapy. Oral steroid pulse therapy can be considered as the first-line treatment for patients with severe AA of recent onset within one year.
引用
收藏
页码:471 / 474
页数:4
相关论文
共 50 条
  • [41] Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis A retrospective observational study
    Waki, Daisuke
    Nishimura, Keisuke
    Tokumasu, Hironobu
    Kadoba, Keiichiro
    Mukoyama, Hiroki
    Saito, Rintaro
    Murabe, Hiroyuki
    Yokota, Toshihiko
    MEDICINE, 2020, 99 (08)
  • [42] High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma
    K W Zamkoff
    M D Matulis
    A C Mehta
    M W Beaty
    R E Hutchison
    T C Gentile
    Bone Marrow Transplantation, 2004, 33 : 635 - 638
  • [43] High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma
    Zamkoff, KW
    Matulis, MD
    Mehta, AC
    Beaty, MW
    Hutchison, RE
    Gentile, TC
    BONE MARROW TRANSPLANTATION, 2004, 33 (06) : 635 - 638
  • [44] Effect of high-dose intravenous methylprednisolone pulse (IVMP) therapy in the survival of patients with anti-melanoma differentiation-associated gene 5-related rapidly progressive interstitial lung disease: a retrospective analysis
    Fan, Li
    Li, Yan
    Lyu, Wenting
    Xu, Qingqing
    Gao, Yujuan
    Qiu, Xiaohua
    Cai, Hourong
    Dai, Jinghong
    CLINICAL RHEUMATOLOGY, 2024, 43 (03) : 1135 - 1143
  • [45] Effect of high-dose intravenous methylprednisolone pulse (IVMP) therapy in the survival of patients with anti-melanoma differentiation-associated gene 5-related rapidly progressive interstitial lung disease: a retrospective analysis
    Li Fan
    Yan Li
    Wenting Lyu
    Qingqing Xu
    Yujuan Gao
    Xiaohua Qiu
    Hourong Cai
    Jinghong Dai
    Clinical Rheumatology, 2024, 43 : 1135 - 1143
  • [46] Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial
    Giacchetti, Sylvie
    Laas, Enora
    Bachelot, Thomas
    Lemonnier, Jerome
    Andre, Fabrice
    Cameron, David
    Bliss, Judith
    Chabaud, Sylvie
    Hardy-Bessard, Anne -Claire
    Lacroix-Triki, Magali
    Canon, Jean -Luc
    Debled, Marc
    Campone, Mario
    Cottu, Paul
    Dalenc, Florence
    Ballesta, Annabelle
    Penault-Llorca, Frederique
    Asselain, Bernard
    Dumas, Elise
    Reyal, Fabien
    Gougis, Paul
    Levi, Francis
    Hamy, Anne-Sophie
    EBIOMEDICINE, 2024, 104
  • [47] IMPROVED DISEASE-FREE SURVIVAL OF CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA AT HIGH-RISK FOR EARLY RELAPSE WITH THE NEW-YORK REGIMEN - A NEW INTENSIVE THERAPY PROTOCOL - A REPORT FROM THE CHILDRENS CANCER STUDY-GROUP
    STEINHERZ, PG
    GAYNON, P
    MILLER, DR
    REAMAN, G
    BLEYER, A
    FINKLESTEIN, J
    EVANS, RG
    MEYERS, P
    STEINHERZ, LJ
    SATHER, H
    HAMMOND, D
    JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (05) : 744 - 752
  • [48] Relationship Between Inflammation and Benefits of Early High-Dose Rosuvastatin on Contrast-Induced Nephropathy in Patients With Acute Coronary Syndrome The Pathophysiological Link in the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention)
    Toso, Anna
    Leoncini, Mario
    Maioli, Mauro
    Tropeano, Francesco
    Di Vincenzo, Emilio
    Villani, Simona
    Bellandi, Francesco
    JACC-CARDIOVASCULAR INTERVENTIONS, 2014, 7 (12) : 1421 - 1429
  • [49] Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0–45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol
    Linea Natalie Toksvang
    Bodil Als-Nielsen
    Christopher Bacon
    Ruta Bertasiute
    Ximo Duarte
    Gabriele Escherich
    Elín Anna Helgadottir
    Inga Rinvoll Johannsdottir
    Ólafur G. Jónsson
    Piotr Kozlowski
    Cecilia Langenskjöld
    Kristi Lepik
    Riitta Niinimäki
    Ulrik Malthe Overgaard
    Mari Punab
    Riikka Räty
    Heidi Segers
    Inge van der Sluis
    Owen Patrick Smith
    Marion Strullu
    Goda Vaitkevičienė
    Hilde Skuterud Wik
    Mats Heyman
    Kjeld Schmiegelow
    BMC Cancer, 22
  • [50] Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol
    Toksvang, Linea Natalie
    Als-Nielsen, Bodil
    Bacon, Christopher
    Bertasiute, Ruta
    Duarte, Ximo
    Escherich, Gabriele
    Helgadottir, Elin Anna
    Johannsdottir, Inga Rinvoll
    Jonsson, Olafur G.
    Kozlowski, Piotr
    Langenskjold, Cecilia
    Lepik, Kristi
    Niinimaki, Riitta
    Overgaard, Ulrik Malthe
    Punab, Mari
    Raty, Riikka
    Segers, Heidi
    van der Sluis, Inge
    Smith, Owen Patrick
    Strullu, Marion
    Vaitkeviciene, Goda
    Wik, Hilde Skuterud
    Heyman, Mats
    Schmiegelow, Kjeld
    BMC CANCER, 2022, 22 (01)